FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310099687> ?p ?o ?g. }

• W4310099687 endingPage "11958" @default.
• W4310099687 startingPage "11956" @default.
• W4310099687 abstract "Introduction. Several studies have examined the impact of BMI on outcomes in B-cell non-Hodgkin lymphoma (B-NHL) but most focused on the impact of pretreatment BMI on outcomes in newly diagnosed patients. In addition, data on weight change patterns during treatment in B-NHL are limited. Herein, we report weight change patterns during sequential lines of treatment and the impact of BMI on outcomes in patients with r/r aggressive large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Methods. Patients with r/r LBCL, FL or MCL were identified through LION, a consortium of 7 US academic institutions that prospectively collects molecular and clinical data on adult patients with r/r B-NHL. Patients with available weight data at time of initiation of the 2nd (Wt-2) and/or 3rd (Wt-3) line of treatment were included. Changes in weight were categorized into no change (-5% to 5%), decrease (≥-5%), or increase (≥5%) from prior line of therapy. Outcomes were evaluated for the 1st three lines of treatment, with the corresponding event-free survival (EFS) for each line of treatment calculated from treatment initiation until progression, new treatment, or death due to any cause; lymphoma-specific survival (LSS) from treatment initiation until death due to lymphoma; and overall survival (OS) from treatment initiation until death from any cause. Results. Of 614 patients, 413 (67.2%) had available Wt-2 (n=354) and/or Wt-3 (n=245) and were included. LBCL was the most common lymphoma subtype (n=193, 46.7%) followed by FL (n=146, 35.3%) and MCL (n=74, 17.9%) (Table). The baseline characteristics at diagnosis for the overall cohort were: median age 60 years (range 17-86), male 60%, White 89% (available n=400), Black 9%, stage III/IV 85% (available n=377), elevated LDH 48% (available n=179), B symptoms present 30% (available n=339), weight loss as a B symptom 11% (available n=413), and performance status ≥2 10% (available n=219). Most patients (n=327, 80%) received chemoimmunotherapy as their first-line treatment (available n=412) and 43% relapsed within 1 year of first treatment. At time of initiation of 1st, 2nd and 3rd lines of treatment, most patients were either overweight (BMI=25-29.9) (37%, 31%, and 36% respectively) or obese (BMI ≥30) (37%, 42%, and 37%, respectively). Weight changes between sequential lines of treatment were common: between 1st and 2nd line treatments (available n=214): 49 patients (23%) had weight decrease, 104 (49%) no change, and 61 (29%) increase; between 2nd and 3rd line treatments (available n=186): 43 patients (23%) had weight decrease, 113 (61%) no change, and 30 (16%) increase. Higher BMI prior to initiation of 3rd line treatment was associated with LSS with overweight and obese patients having superior LSS compared with patients with normal BMI (hazard ratio (HR): 0.27 (95% confidence interval (CI), 0.08-0.89), p=.031 and HR=0.32 (95%CI 0.11-0.95), p=.04, respectively) (Figure). BMI prior to initiation of 1st, 2nd, or 3rd lines of treatment was not significantly associated with outcomes otherwise. Weight changes between sequential lines of treatment were not significantly associated with EFS, LSS, or OS. Conclusions. Obesity is common among patients with r/r B-NHL. Weight changes during sequential lines of treatment are also common in patients with r/r B-NHL with approximately 40-50% of patients losing or gaining ≥5% of their pretreatment body weight. However, these weight changes were not associated with outcomes in our study. Finally, patients with higher BMI (overweight or obese) prior to initiation of third-line treatment had a significantly lower risk of death from lymphoma compared with patients with normal BMI. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310099687 created "2022-11-30" @default.
• W4310099687 creator A5007477825 @default.
• W4310099687 creator A5017559837 @default.
• W4310099687 creator A5023426390 @default.
• W4310099687 creator A5024389256 @default.
• W4310099687 creator A5027411179 @default.
• W4310099687 creator A5031412066 @default.
• W4310099687 creator A5043541884 @default.
• W4310099687 creator A5055948859 @default.
• W4310099687 creator A5057234924 @default.
• W4310099687 creator A5060834552 @default.
• W4310099687 creator A5064091455 @default.
• W4310099687 creator A5083450833 @default.
• W4310099687 date "2022-11-15" @default.
• W4310099687 modified "2023-09-29" @default.
• W4310099687 title "Weight Change Trends and Impact of Body Mass Index (BMI) on Outcomes in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, a Retrospective Analysis from the Lymphoma Innovations Orien Network (LION) Consortium" @default.
• W4310099687 doi "https://doi.org/10.1182/blood-2022-163681" @default.
• W4310099687 hasPublicationYear "2022" @default.
• W4310099687 type Work @default.
• W4310099687 citedByCount "0" @default.
• W4310099687 crossrefType "journal-article" @default.
• W4310099687 hasAuthorship W4310099687A5007477825 @default.
• W4310099687 hasAuthorship W4310099687A5017559837 @default.
• W4310099687 hasAuthorship W4310099687A5023426390 @default.
• W4310099687 hasAuthorship W4310099687A5024389256 @default.
• W4310099687 hasAuthorship W4310099687A5027411179 @default.
• W4310099687 hasAuthorship W4310099687A5031412066 @default.
• W4310099687 hasAuthorship W4310099687A5043541884 @default.
• W4310099687 hasAuthorship W4310099687A5055948859 @default.
• W4310099687 hasAuthorship W4310099687A5057234924 @default.
• W4310099687 hasAuthorship W4310099687A5060834552 @default.
• W4310099687 hasAuthorship W4310099687A5064091455 @default.
• W4310099687 hasAuthorship W4310099687A5083450833 @default.
• W4310099687 hasBestOaLocation W43100996871 @default.
• W4310099687 hasConcept C121332964 @default.
• W4310099687 hasConcept C126322002 @default.
• W4310099687 hasConcept C141071460 @default.
• W4310099687 hasConcept C142424586 @default.
• W4310099687 hasConcept C143998085 @default.
• W4310099687 hasConcept C167135981 @default.
• W4310099687 hasConcept C2778559949 @default.
• W4310099687 hasConcept C2779338263 @default.
• W4310099687 hasConcept C2780221984 @default.
• W4310099687 hasConcept C71924100 @default.
• W4310099687 hasConcept C87355193 @default.
• W4310099687 hasConceptScore W4310099687C121332964 @default.
• W4310099687 hasConceptScore W4310099687C126322002 @default.
• W4310099687 hasConceptScore W4310099687C141071460 @default.
• W4310099687 hasConceptScore W4310099687C142424586 @default.
• W4310099687 hasConceptScore W4310099687C143998085 @default.
• W4310099687 hasConceptScore W4310099687C167135981 @default.
• W4310099687 hasConceptScore W4310099687C2778559949 @default.
• W4310099687 hasConceptScore W4310099687C2779338263 @default.
• W4310099687 hasConceptScore W4310099687C2780221984 @default.
• W4310099687 hasConceptScore W4310099687C71924100 @default.
• W4310099687 hasConceptScore W4310099687C87355193 @default.
• W4310099687 hasIssue "Supplement 1" @default.
• W4310099687 hasLocation W43100996871 @default.
• W4310099687 hasOpenAccess W4310099687 @default.
• W4310099687 hasPrimaryLocation W43100996871 @default.
• W4310099687 hasRelatedWork W2003938723 @default.
• W4310099687 hasRelatedWork W2047967234 @default.
• W4310099687 hasRelatedWork W2118496982 @default.
• W4310099687 hasRelatedWork W2351796763 @default.
• W4310099687 hasRelatedWork W2364998975 @default.
• W4310099687 hasRelatedWork W2439875401 @default.
• W4310099687 hasRelatedWork W2554612586 @default.
• W4310099687 hasRelatedWork W2567738959 @default.
• W4310099687 hasRelatedWork W4238867864 @default.
• W4310099687 hasRelatedWork W2525756941 @default.
• W4310099687 hasVolume "140" @default.
• W4310099687 isParatext "false" @default.
• W4310099687 isRetracted "false" @default.
• W4310099687 workType "article" @default.